Vertex adds Daniel Brennan to board, expands to eleven directors

Vertex Pharmaceuticals disclosed in an 8-K filing that Daniel Brennan joined the company's board of directors on October 20, 2026, a move that expanded the board from ten to eleven members.¹ Brennan also joined the Audit and Finance Committee.¹

Brennan brings a finance background from the medical device sector. He held the role of Executive Vice President and Chief Financial Officer at Boston Scientific Corporation, described in the filing as a medical device and healthcare technology company, from January 2014 until retiring in June 2025.¹ Earlier in his career at Boston Scientific, he was Senior Vice President, Corporate Controller from 2010 through 2013, and held a series of finance roles with growing responsibility from 1996 to 2009.¹

Brennan's other board memberships include two active and one former. He has sat on the board of Waters Corporation, which the filing identifies as a publicly listed maker of analytical instruments and software, since November 2022, and on the board of Madrigal Pharmaceuticals, described as a publicly traded biopharmaceutical company, since August 2025.¹ He previously served on the board of Nuance Corporation, a publicly traded communication company according to the filing, until Microsoft Corporation acquired it in March 2022.¹ Brennan holds a bachelor's degree in finance and investments and an MBA from Babson College, and he is a certified public accountant.¹

On compensation, Brennan received a $400,000 restricted stock unit award upon joining the board, set to vest in October 2027.¹ The filing also states that there are no reportable transactions between Vertex and Brennan under Item 404(a) of Regulation S-K, and no arrangement or understanding existed between Brennan and any other party regarding his appointment.¹